Kanis J A, Johnell O, Oden A, De Laet C, Oglesby A, Jönsson B
Centre for Metabolic Bone Diseases (WHO Collaborating Centre), University of Sheffield Medical School, Sheffield, UK.
Bone. 2002 Jul;31(1):26-31. doi: 10.1016/s8756-3282(02)00813-x.
The aim of this study was to determine the threshold of fracture probability at which interventions become cost-effective. We modeled the effects of a treatment costing $500/year, given for 5 years, that decreased the risk of all osteoporotic fractures by 35%, followed by a waning of effect for 5 years. Sensitivity analyses included a range of effectiveness (10%-50%) and a range of intervention costs (200-500 dollars/year). Data on costs and risks were from Sweden. Costs included direct costs and costs in added years of life, but excluded indirect costs due to morbidity. A threshold for cost-effectiveness of 60,000 dollars per quality-adjusted life-year (QALY) gained was used. Costs of added years were excluded in a sensitivity analysis for which a threshold value of 30,000 dollars per QALY was used. In the base case, intervention was cost-effective when treatment was targeted to women at average risk at age of >or=65 years. Irrespective of the efficacy modeled (10%-50%) or of cost of intervention (200-500 dollars/year) segments of the population at average risk could be targeted cost-effectively: The lower the intervention cost and the higher the effectiveness, the lower the age at which intervention was cost-effective. With the base case (500 dollars/year; 35% efficacy) treatment in women was cost-effective with a 10 year hip fracture probability that ranged from 1.4% at the age of 50 years to 4.4% at the age of 65 years. The exclusion of osteoporotic fractures other than hip fracture would increase the threshold to a 9%-11% 10 year probability because of the substantial morbidity from fractures other than hip fracture, particularly at younger ages. We conclude that the inclusion of all osteoporotic fractures has a marked effect on intervention thresholds, that these vary with age, and that available treatments can be cost-effectively targeted to individuals at moderately increased risk.
本研究的目的是确定干预措施具有成本效益时的骨折概率阈值。我们对一种每年花费500美元、持续5年的治疗效果进行了建模,该治疗可使所有骨质疏松性骨折的风险降低35%,随后效果逐渐减弱,持续5年。敏感性分析包括一系列有效性(10%-50%)和一系列干预成本(每年200-500美元)。成本和风险数据来自瑞典。成本包括直接成本和增加生命年数的成本,但不包括发病导致的间接成本。使用的成本效益阈值为每获得一个质量调整生命年(QALY)60,000美元。在一项敏感性分析中,排除了增加生命年数的成本,该分析使用的阈值为每QALY 30,000美元。在基础案例中,当针对65岁及以上平均风险的女性进行治疗时,干预措施具有成本效益。无论建模的疗效如何(10%-50%)或干预成本如何(每年200-500美元),平均风险人群的部分群体都可以通过具有成本效益的方式进行干预:干预成本越低,有效性越高,干预具有成本效益的年龄就越低。在基础案例(每年500美元;35%疗效)中,女性治疗具有成本效益的10年髋部骨折概率在50岁时为1.4%,在65岁时为4.4%。排除髋部骨折以外的骨质疏松性骨折会将阈值提高到10年概率的9%-11%,因为髋部骨折以外的骨折,特别是在较年轻年龄段,会导致大量发病。我们得出结论,纳入所有骨质疏松性骨折对干预阈值有显著影响,这些阈值随年龄而异,并且现有的治疗方法可以以具有成本效益的方式针对中度风险增加的个体。